HOXA10 and sarcoma: In conclusion, the present study found that there was reduced levels of CD4+ T cells in peripheral blood, reduced levels of IFN-γ and TNF-α, and upregulation of the HOXA10 gene in sarcoma patients compared to healthy volunteers, which suggests that sarcoma patients have reduced Th1 immune response, i.e., anticancer immunity.